Food and Drug Administration FDA for iloperidone an investigational atypical antipsychotic for the treatment of schizophrenia. The application includes data from clinical trials and more than patients treated with iloperidone. The submission of the iloperidone NDA marks a significant milestone for Vanda. The NIMH funded CATIE effectiveness study revealed the efficacy or safety limitations of current agents. About Vanda Pharmaceuticals Inc. The company has three product candidates in clinical development. For more on Vanda Pharmaceuticals Inc. please visit http www. Such forward looking statements are based upon current expectations that involve risks changes in circumstances assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. No forward looking statements can be guaranteed and actual results may differ materially from such statements. pages Stem Cells pub.

S! ource: http://www.bio.com/newsfeatures/newsfeatures_industry.jhtml;jsessionid=CG5VOJZIG5ECZR3FQLMCFEWHUWBNSIV0?cid=34300002